Jin Pyo HongAkramul Zikri Abd MalekCheng‐Ta LiJong‐Woo PaikAhmad Hatim SulaimanGilbert MadriagaJianmin ZhuoSarah SigginsDong‐Jing FuPo‐Chung Ju2026-02-032026-02-032023-09-2810.1111/appy.12548https://scholars.csmu.edu.tw/handle/123456789/4832<jats:title>Abstract</jats:title><jats:p>This post‐hoc analysis evaluated the efficacy and safety of intranasal esketamine in the Asian subgroup from ASPIRE I. Patients with major depressive disorder and suicidal ideation with intent received intranasal esketamine (<jats:italic>n</jats:italic> = 26) or placebo (<jats:italic>n</jats:italic> = 27), plus standard of care for 25 days. The primary endpoint was the change in Montgomery‐Åsberg Depression Rating Scale (MADRS) total score from baseline to Day 2. The MADRS score improved in favor of esketamine (least squares mean difference: −3.8). No unexpected safety concerns were noted. The Asian subgroup showed a similar efficacy and safety profile as the total ASPIRE I cohort.</jats:p>[SDGs]SDG3Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of <scp>ASPIRE</scp> I (a randomized, double‐blind, placebo‐controlled study)journal-article